Nanosonics Limited (ASX:NAN) Investor Presentation 7 December 2009
Disclaimer Summary information Forward looking statements This presentation contains summary information of Nanosonics Limited (“NAN”) This presentation contains certain forward-looking statements. The words 'anticipate', and is dated 7 December 2009. The information in this presentation does not 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', purport to be complete or comprehensive, and does not purport to summarise all 'target', 'plan' and other similar expressions are intended to identify forward-looking information that an investor should consider when making an investment decision. statements. Indications of, and guidance on, future earnings and financial position It should be read in conjunction with NAN’s other periodic and continuous and performance are also forward-looking statements. Such forward-looking disclosure announcements lodged with the Australian Securities Exchange statements are not guarantees of future performance and involve known and (“ASX”), which are available at www.asx.com.au. unknown risks, uncertainties and other factors, many of which are beyond the control of NAN, that may cause actual results to differ materially from those expressed or y y p implied in such statements. There can be no assurance that actual outcomes will not Not investment advice differ materially from these statements. You should not place reliance on forward- This presentation is not a prospectus or a product disclosure statement under the looking statements and neither NAN nor any of its directors, employees, servants, Corporations Act 2001 (Cth) and has not been lodged with the Australian advisers or agents assume any obligation to update such information. Securities and Investment Commission (“ASIC”). The offer of NAN shares (“New Shares”) to which this presentation relates complies with the requirements of Not for distribution or release in the United States section 708A(5) of the Corporations Act and a “cleansing notice” complying with section 708A(5)(e) will be lodged with the ASX. The information provided in this This presentation has been prepared for publication in Australia and may not be presentation is not intended to be (and may not be) relied upon as advice to presentation is not intended to be (and may not be) relied upon as advice to distributed or released in the United States This presentation does not constitute an distributed or released in the United States. This presentation does not constitute an investors or potential investors and has been prepared without taking into account offer for sale, or the solicitation of an offer to buy, any shares in the United States or the recipient’s investment objectives, financial circumstances or particular needs. in any other jurisdiction in which such an offer would be illegal, or to, or for the Those individual objectives, circumstances and needs should be considered, with account or benefit of, any US Person (as defined in Regulation S under the US independent professional advice, when deciding if an investment is appropriate. Securities Act of 1933, as amended (the “Securities Act) (“US Person”)). The New Cooling-off rights do not apply to an investment in any New Shares. Shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States and, accordingly, may not be offered or sold in the United States or to, or for the account or benefit of, Financial data US Persons except in transactions exempt from, or not subject to, the registration US Persons except in transactions exempt from or not subject to the registration All dollar values are in Australian dollars (A$) and financial data is presented within requirements of such Act and applicable US state securities laws. the financial year end of 30 June unless otherwise stated. Other jurisdictions Risks of investment The New Shares may not be offered or sold in any jurisdiction other than Australia An investment in NAN shares is subject to investment and other known and and New Zealand under the Offer, except to persons to whom such offer or sale of unknown risks, some of which are beyond the control of NAN. NAN does not New Shares or distribution of this presentation is permitted under applicable law. guarantee any particular rate of return or the performance of NAN nor does it guarantee the repayment of capital from NAN or any particular tax treatment. You t th t f it l f NAN ti l t t t t Y should have regard to (among other things) the risks outlined in this presentation.
Contents Executive summary 1. Introduction to Nanosonics 2. Trophon – a breakthrough product 3. Product Development Opportunities p pp 4. Anticipated news flow 5 5. Key Risks Key Risks 6. Capital Raising 7 7. Investment Highlights Investment Highlights
Executive Summary Executive Summary • Nanosonics is seeking to raise A$12 million via an underwritten placement g $ p • Funds will be applied to: • support the rapid acceleration of growth both in terms of production and marketing support to drive the launch product (Trophon ultrasound probe re- marketing support to drive the launch product (Trophon ultrasound probe re processor) in order to meet potential market demand; • fund, develop and manufacture new products in-house in order to maximise shareholder value through ownership of the complete value chain. The Company has validated significant additional business opportunities in the healthcare market which leverage the existing IP portfolio. These include single lumen endoscope reprocessing and bed disinfection products, as well as environmental hard surface decontamination and scientific laboratory decontamination; and • relocate to larger premises which will support the expansion of the manufacturing capacity of the Trophon EPR from 2,000 units on a single shift to approximately 10,000 units. Nanosonics anticipates that it will manufacture future products in the same site same site
Acceleration of Trophon Sales Region Indicators of increased demand Estimated market potential ANZ • High level disinfection (“HLD”) recommended between patients by • A$40 million the Australian Government • 2,000 Trophon units • Professional bodies support guidelines • In principle agreement to purchase 200+ units from a national account (estimated 10% market penetration) t ( ti t d 10% k t t ti ) France • National move banning glutaraldehydes with requirement for HLD • A$100 million • Conversations underway with key opinion leaders to establish • 7,000 Trophon units Europe wide ISO standards for disinfection of ultrasound probes England • Current concerns around infection control • A$70 million • Standards driving the increased awareness of automated • 5,000 Trophon units procedures • Nanosonics has commenced discussions with the National Imaging Body to develop nationwide standards for ultrasound probe reprocessing North • Centre for Disease Control (CDC) recommends the use of • A$500 million America hydrogen peroxide for HLD of intracavity probes • >20,000 Trophon units • Indications of strong demand from potential distributors Indications of strong demand from potential distributors ROW • Japan & Asia represent significant opportunities for growth • A$400 million (Japan) 5
Accelerated product development • Nanosonics will accelerate the internal development of a suite of new products whilst p p maintaining total control of the value chain • This will increase shareholder returns via: • owning and controlling all IP related to new products; • d t determining its own business priorities and adding value to the product based i i it b i i iti d ddi l t th d t b d upon market feedback; • owning the complete value chain from development through to manufacturing, which will allow superior returns for each product manifestation; and • producing fully validated and commercially available assets for sale • By controlling the complete product value chain the Company will be in a position to maximise distribution agreements with potential business partners who will pay a premium for fully approved revenue producing sales opportunities premium for fully approved revenue producing sales opportunities
Accelerated product development Leveraging current platform technologies into a leadership position in low temperature point of care disinfection point of care disinfection Trophon Platform Xonar Platform • Trophon EPR (ultrasound probe • Bed decontamination di i f disinfection) ti ) • Room / surface decontamination • Single lumen probe disinfection • Scientific laboratory decontamination • TEE probe disinfection • Significant market potential • Rigid endoscope disinfection • Significant market potential
1. Introduction to Nanosonics
Recommend
More recommend
